查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2081979

緩釋注射劑市場：按產品類型、聚合物類型、給藥途徑、應用和最終用戶分類的全球市場預測，2026-2032年

Sustained Release Injectables Market by Product Type, Polymer Type, Route Of Administration, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，緩釋注射藥物市場將成長至 40.1 億美元，複合年成長率為 7.24%。

主要市場統計數據
基準年 2025 24.5億美元
預計年份：2026年 26億美元
預測年份 2032 40.1億美元
複合年成長率 (%) 7.24%

緩釋注射劑正在重塑藥物遞送方式，將治療效果持續時間從幾天延長至幾個月，減輕給藥負擔，並提高慢性病、精神健康、腫瘤、內分泌疾病、感染疾病預防和避孕等領域的用藥依從性。此類製劑包括長效注射劑、儲庫製劑、聚合物微球、體內形成的儲存庫、脂質體系統、植入和奈米顆粒平台。

這項需求得到了已證實的公共衛生因素的支持。世界衛生組織（WHO）指出，全球大多數死亡是由非傳染性疾病造成的，而包括美國食品藥物管理局（FDA）和歐洲藥品管理局（EMA）在內的監管機構正在持續評估能夠改善治療連續性並簡化醫療服務流程的長效產品。對於製藥公司而言，緩釋注射劑兼具高臨床價值，並滿足了先進的製劑科學、無菌生產、無菌保證、緩釋分析和生命週期管理等方面的要求。

緩釋注射藥物領域的變革性變化

緩釋注射劑領域的發展正從基於便利性重新設計製劑轉向基於實證醫學重新設計療法。已獲批准的用於抗精神病、HIV治療和預防、激素調節、物質使用障礙、避孕和代謝紊亂的長效療法表明，延長給藥間隔可以改變關於患者治療參與度、臨床工作流程以及支付方價值的討論。

人工智慧對產品開發的累積影響

人工智慧對緩釋注射劑的研發正產生日益顯著的影響，其應用範圍涵蓋分子篩檢、輔料篩選、釋放曲線預測、穩定性評估、放大生產風險評估以及生產偏差分析等各個環節。基於高品質理化性質、穩定性、溶離度、體外釋放和藥物動力學資料集訓練的機器學習模型，能夠幫助確定製劑變數的優先級，並縮短實驗週期。

全球市場的關鍵區域洞察

亞太地區正成為緩釋注射劑的關鍵成長驅動力。中國、印度、日本、韓國和澳洲擁有大規模的病患群體，能夠擴大專科醫療服務的覆蓋範圍，並具備強大的生產能力。中國和印度在藥用活性成分、學名藥、製劑研發和契約製造擁有規模優勢，而日本、韓國和澳洲則建立了先進的臨床、監管、生物製藥和品管基礎設施。該地區的需求成長主要受慢性病負擔加重、專科藥物使用量增加以及公共部門加強國內藥品供應等因素的推動。

深入了解影響供需的關鍵群體

隨著監管協調、醫院現代化和國內醫藥投資的推進，複雜注射劑在東南亞地區上市的可能性越來越大，東協市場的重要性也日益凸顯。儘管各國需求模式不盡相同，但由於非傳染性疾病盛行率上升、全民健康覆蓋（UHC）計劃的擴大以及三級醫療體系的加強，人們對長效注射療法的興趣日益濃厚。海灣合作理事會（GCC）成員國的特點是集中採購系統、部分成員國醫療保健支出較高、國家工業化計劃以及對本地灌裝、生物製藥和無菌注射劑生產能力的日益重視。

各國對緩釋注射藥物策略的關鍵見解

美國在長效製劑的商業化進程、臨床試驗密度、特種用途注射劑的應用以及監管經驗方面均處於領先地位。而加拿大則更注重實證報銷、醫療技術評估和准入管理。墨西哥和巴西是拉丁美洲重要的品牌和非專利注射劑中心；墨西哥利用接近性，而巴西則透過公共採購、國家免疫規劃、公共衛生基礎設施以及對國內生產的獎勵，實現了規模經濟。

為行業領導者提供的實用建議

產業領導者應優先考慮那些延長給藥間隔能夠直接改善用藥依從性、治療維持率、預防復發、擴大公共衛生覆蓋範圍或提高醫療系統效率的適應症。早期目標產品特性（TPP）的開發應整合病患偏好、注射部位耐受性、劑量、針頭規格、醫護人員給藥時間、儲存條件、處置要求以及對真實世界資料（RWE）的期望等因素。

調查方法

本調查方法基於結構化的二手研究和檢驗框架，利用公開的監管、科學和醫療保健相關資訊來源。主要參考資料包括FDA資料庫和指導文件、EMA歐洲公共評估報告、WHO健康統計數據、OECD和世界銀行指標、國家保險報銷出版刊物、藥典參考資料以及公開的監管資訊披露。

結論

緩釋注射劑正成為現代藥物遞送系統的重要戰略支柱。這是因為它們解決了醫療保健領域一個已被證實的難題：許多慢性疾病和預防性療法因給藥頻率過高、治療方案複雜或與患者用藥習慣不符而導致療效不佳。在強力的臨床和生產證據支持下，長效注射劑能夠提高患者的用藥依從性，簡化治療模式，支持預防性醫療保健項目，並打造差異化的產品生命週期。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：緩釋注射劑市場：依產品類型分類

  • 墨水匣
  • 嵌入式泵浦
  • 預填充式注射器
  • 未填充的管瓶

第8章：緩釋注射劑市場：依聚合物類型分類

  • 可生物分解聚合物
    • PCL
    • PLA
    • PLGA
  • 不可生物分解聚合物
    • 聚乙烯
    • 聚矽氧烷

第9章：緩釋注射劑市場：依給藥途徑分類

  • 硬脊膜外麻醉
  • 肌肉內部
  • 玻璃體腔內
  • 皮下

第10章：緩釋注射劑市場：依應用領域分類

  • 荷爾蒙療法
  • 腫瘤學
    • 骨髓惡性腫瘤
    • 固體癌
      • 乳癌
      • 肺癌
  • 疼痛管理
  • 疫苗

第11章：緩釋注射劑市場：以最終用戶分類

  • 門診手術中心
  • 診所
  • 家庭醫療保健
  • 醫院

第12章：緩釋注射劑市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章：緩釋注射劑市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：緩釋注射劑市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • AbbVie Inc.
  • Alkermes plc
  • Amgen Inc.
  • Amneal Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Catalent, Inc.
  • Cipla Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Hikma Pharmaceuticals PLC
  • Indivior PLC
  • Ipsen SA
  • Janssen Pharmaceuticals, Inc.
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Merck & Co., Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Recipharm AB
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Tolmar, Inc.
  • UCB SA
  • Viatris Inc.
  • Zydus Lifesciences Limited
Product Code: MRR-43078BB92C8D

The Sustained Release Injectables Market is projected to grow by USD 4.01 billion at a CAGR of 7.24% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.45 billion
Estimated Year [2026] USD 2.60 billion
Forecast Year [2032] USD 4.01 billion
CAGR (%) 7.24%

Sustained release injectables are reshaping drug delivery by extending therapeutic exposure from days to months, reducing dosing burden, and supporting adherence in chronic diseases, behavioral health, oncology, endocrine disorders, infectious disease prevention, and contraception. The category includes long-acting injectables, depot formulations, polymeric microspheres, in situ forming depots, lipid-based systems, implants, and nanoparticle-enabled platforms.

Demand is supported by verified public-health fundamentals: the World Health Organization reports that noncommunicable diseases account for most global deaths, while regulators, including the FDA and EMA, continue to evaluate long-acting products that can improve persistence and simplify care delivery. For pharmaceutical manufacturers, sustained release injectables combine high clinical value with demanding formulation science, aseptic manufacturing, sterility assurance, controlled-release analytics, and lifecycle management requirements.

Transformative Shifts in the Sustained Release Injectable Landscape

The sustained release injectable landscape is moving from convenience-driven reformulation toward evidence-led therapeutic redesign. Approved long-acting therapies in antipsychotics, HIV treatment and prevention, hormone modulation, substance-use disorder, contraception, and metabolic disease have demonstrated that extended dosing intervals can change patient engagement, clinical workflows, and payer value discussions.

At the same time, the sector is becoming more technically specialized. Developers must align release kinetics, particle-size distribution, polymer degradation, syringeability, extractables and leachables, cold-chain needs, sterilization strategy, and bioequivalence approaches. The most competitive development models integrate formulation, device, analytics, manufacturing, regulatory, and patient-support capabilities earlier in development rather than treating sustained release as a late-stage product extension.

Cumulative Impact of Artificial Intelligence on Product Development

Artificial intelligence is increasingly influencing sustained release injectable development across molecule selection, excipient screening, release-profile prediction, stability assessment, scale-up risk evaluation, and manufacturing deviation analysis. Machine learning models can help prioritize formulation variables and reduce experimental cycles when trained on high-quality physicochemical, stability, dissolution, in vitro release, and pharmacokinetic datasets.

The cumulative impact is strongest when AI is embedded within validated quality systems. In silico modeling, digital twins, process analytical technology, and automated visual inspection can improve consistency, but regulated implementation still requires data integrity, model explainability, human oversight, cybersecurity controls, and compliance with FDA, EMA, ICH, and GxP expectations. AI is therefore an accelerator for better decisions, not a substitute for robust CMC evidence.

Key Regional Insights Across Global Markets

Asia-Pacific is becoming a critical growth engine for sustained release injectables as China, India, Japan, South Korea, and Australia combine large patient populations, expanding specialty-care access, and strong manufacturing capabilities. China and India provide scale in active pharmaceutical ingredients, generics, formulation development, and contract manufacturing, while Japan, South Korea, and Australia contribute advanced clinical, regulatory, biologics, and quality-system infrastructure. Regional demand is supported by the high burden of chronic disease, rising use of specialty medicines, and public-sector efforts to strengthen domestic pharmaceutical supply.

North America remains a leading innovation and commercialization hub, supported by established FDA regulatory pathways, specialty pharmacy channels, clinical-trial infrastructure, and documented adoption of long-acting therapies in mental health, HIV, contraception, and chronic disease management. Europe benefits from EMA scientific procedures, country-level health technology assessment systems, pharmacovigilance rigor, and strong sterile injectable manufacturing clusters. Latin America, led by Brazil and Mexico, shows demand linked to public-health programs, urban specialty care, and growing experience with complex injectables, while the Middle East is prioritizing healthcare investment, centralized procurement, local fill-finish capacity, and reliable cold-chain systems. Across Africa, access strategies are shaped by essential medicines programs, infectious disease prevention needs, donor-supported procurement mechanisms, and the practical value of long-acting products that reduce visit frequency and strengthen continuity of care.

Key Group Insights Shaping Demand and Supply

ASEAN markets are gaining relevance as regulatory convergence initiatives, hospital modernization, and domestic pharmaceutical investment improve the feasibility of launching complex injectables across Southeast Asia. Demand patterns differ by country, but rising noncommunicable disease prevalence, expanding universal health coverage efforts, and growing tertiary-care capacity support interest in long-acting injectable therapies. The GCC is characterized by centralized procurement, high healthcare spending in several member states, national industrialization plans, and growing interest in local fill-finish, biologics, and sterile injectable capacity.

The European Union provides a harmonized regulatory base through EMA procedures while still requiring country-level pricing, reimbursement, and health technology assessment execution. BRICS countries combine large disease burdens with manufacturing scale, policy interest in domestic production, and expanding clinical research capabilities, making localization and affordability important strategic themes. G7 markets remain central for premium innovation, clinical adoption, intellectual-property monetization, and evidence-based reimbursement, while NATO-aligned supply-chain strategies increasingly emphasize resilience for sterile injectables, critical medicines, and medical countermeasures amid documented concerns over medicine shortages and geopolitical supply disruption.

Key Country Insights for Sustained Release Injectable Strategy

The United States leads in commercialization depth, clinical-trial density, specialty injectable adoption, and regulatory experience with long-acting formulations, while Canada emphasizes evidence-based reimbursement, health technology assessment, and access management. Mexico and Brazil are important Latin American platforms for branded and generic injectables, with Mexico benefiting from proximity to North American supply chains and Brazil offering scale through public procurement, national immunization and public-health infrastructure, and domestic production incentives.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine advanced clinical practice with strong payer scrutiny, making pharmacoeconomic evidence, real-world outcomes, and comparative effectiveness important for sustained release injectable strategy. Russia remains a sizeable market with local-production priorities and demand for essential sterile medicines. China and India are central to patient volume, manufacturing capability, clinical expansion, and policy support for domestic pharmaceutical capacity; Japan rewards quality, safety, and differentiated outcomes; Australia offers a transparent reimbursement environment and strong clinical standards; and South Korea contributes advanced biopharma manufacturing, biosimilar expertise, digital health infrastructure, and high-quality clinical research capabilities.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize indications where extended dosing directly improves adherence, persistence, relapse prevention, public-health coverage, or health-system efficiency. Early target-product-profile work should integrate patient preference, injection-site tolerability, dose volume, needle gauge, healthcare professional administration time, storage conditions, disposal requirements, and real-world evidence expectations.

Companies should invest in in vitro release testing, validated analytical methods, scalable aseptic processes, supplier qualification, device compatibility, and sterility assurance before pivotal development. Strategic partnerships with CDMOs, polymer and excipient specialists, device developers, digital adherence platforms, and regional distributors can reduce launch risk. Commercial teams should prepare payer dossiers that link sustained exposure to fewer missed doses, lower care fragmentation, reduced administration burden, and measurable outcomes rather than relying on dosing convenience alone.

Research Methodology

The research methodology is built on a structured secondary research and validation framework using publicly available regulatory, scientific, and healthcare sources. Core references include FDA databases and guidance documents, EMA European public assessment reports, WHO health statistics, OECD and World Bank indicators, national reimbursement publications, pharmacopoeial references, and publicly available regulatory disclosures.

Insights are synthesized through triangulation across therapeutic adoption, regulatory pathways, manufacturing feasibility, clinical evidence, formulation complexity, quality requirements, and regional access conditions. Market statements avoid unsupported revenue projections and focus on verified drivers such as disease burden, approved product precedents, sterile manufacturing constraints, medicine-shortage documentation, public procurement behavior, and policy priorities in medicines access, domestic production, and supply-chain resilience.

Conclusion

Sustained release injectables are becoming a strategic pillar of modern drug delivery because they address a verified healthcare challenge: many chronic and preventive therapies fail when dosing is frequent, complex, or poorly aligned with patient behavior. Long-acting injectable formulations can strengthen adherence, simplify care models, support preventive health programs, and create differentiated product lifecycles when backed by strong clinical and manufacturing evidence.

Future leadership will depend on evidence quality, manufacturability, regulatory execution, regional access planning, and disciplined use of AI-enabled development tools. Organizations that combine formulation science with quality-by-design principles, patient-centered design, robust supply networks, and credible real-world evidence will be best positioned to create value in the sustained release injectable market.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Sustained Release Injectables Market, by Product Type

  • 7.1. Cartridges
  • 7.2. Implantable Pumps
  • 7.3. Pre-Filled Syringes
  • 7.4. Unfilled Vials

8. Sustained Release Injectables Market, by Polymer Type

  • 8.1. Biodegradable Polymers
    • 8.1.1. PCL
    • 8.1.2. PLA
    • 8.1.3. PLGA
  • 8.2. Non-Biodegradable Polymers
    • 8.2.1. Polyethylene
    • 8.2.2. Polysiloxanes

9. Sustained Release Injectables Market, by Route Of Administration

  • 9.1. Epidural
  • 9.2. Intramuscular
  • 9.3. Intravitreal
  • 9.4. Subcutaneous

10. Sustained Release Injectables Market, by Application

  • 10.1. Hormonal Therapies
  • 10.2. Oncology
    • 10.2.1. Hematological Malignancies
    • 10.2.2. Solid Tumors
      • 10.2.2.1. Breast Cancer
      • 10.2.2.2. Lung Cancer
  • 10.3. Pain Management
  • 10.4. Vaccines

11. Sustained Release Injectables Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Clinics
  • 11.3. Home Healthcare
  • 11.4. Hospitals

12. Sustained Release Injectables Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Sustained Release Injectables Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Sustained Release Injectables Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Concentration Analysis, 2025
    • 15.1.1. Concentration Ratio (CR)
    • 15.1.2. Herfindahl Hirschman Index (HHI)
  • 15.2. Recent Developments & Impact Analysis, 2025
  • 15.3. Product Portfolio Analysis, 2025
  • 15.4. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. AbbVie Inc.
  • 16.2. Alkermes plc
  • 16.3. Amgen Inc.
  • 16.4. Amneal Pharmaceuticals, Inc.
  • 16.5. AstraZeneca PLC
  • 16.6. Bayer AG
  • 16.7. Boehringer Ingelheim International GmbH
  • 16.8. Bristol-Myers Squibb Company
  • 16.9. Catalent, Inc.
  • 16.10. Cipla Ltd.
  • 16.11. Dr. Reddy's Laboratories Ltd.
  • 16.12. Eli Lilly and Company
  • 16.13. F. Hoffmann-La Roche Ltd
  • 16.14. Gilead Sciences, Inc.
  • 16.15. GlaxoSmithKline plc
  • 16.16. Hikma Pharmaceuticals PLC
  • 16.17. Indivior PLC
  • 16.18. Ipsen S.A.
  • 16.19. Janssen Pharmaceuticals, Inc.
  • 16.20. Johnson & Johnson Services, Inc.
  • 16.21. Lupin Limited
  • 16.22. Merck & Co., Inc.
  • 16.23. Novartis AG
  • 16.24. Novo Nordisk A/S
  • 16.25. Otsuka Pharmaceutical Co., Ltd.
  • 16.26. Pfizer Inc.
  • 16.27. Recipharm AB
  • 16.28. Sanofi S.A.
  • 16.29. Sun Pharmaceutical Industries Ltd.
  • 16.30. Takeda Pharmaceutical Company Limited
  • 16.31. Teva Pharmaceutical Industries Ltd.
  • 16.32. Tolmar, Inc.
  • 16.33. UCB S.A.
  • 16.34. Viatris Inc.
  • 16.35. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CARTRIDGES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CARTRIDGES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CARTRIDGES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL IMPLANTABLE PUMPS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL IMPLANTABLE PUMPS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL IMPLANTABLE PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PRE-FILLED SYRINGES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PRE-FILLED SYRINGES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PRE-FILLED SYRINGES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL UNFILLED VIALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL UNFILLED VIALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL UNFILLED VIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BIODEGRADABLE POLYMERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BIODEGRADABLE POLYMERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BIODEGRADABLE POLYMERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PCL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PCL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PCL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PLA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PLA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PLA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PLGA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PLGA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PLGA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NON-BIODEGRADABLE POLYMERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NON-BIODEGRADABLE POLYMERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NON-BIODEGRADABLE POLYMERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL POLYETHYLENE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL POLYETHYLENE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL POLYETHYLENE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL POLYSILOXANES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL POLYSILOXANES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL POLYSILOXANES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL EPIDURAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL EPIDURAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL EPIDURAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL INTRAVITREAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL INTRAVITREAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL INTRAVITREAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL HORMONAL THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL HORMONAL THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL HORMONAL THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL SOLID TUMORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL SOLID TUMORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL SOLID TUMORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BREAST CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BREAST CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BREAST CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL LUNG CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL LUNG CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PAIN MANAGEMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PAIN MANAGEMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL HOME HEALTHCARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL HOME HEALTHCARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL HOME HEALTHCARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC SUSTAINED RELEASE INJECTABLES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE SUSTAINED RELEASE INJECTABLES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST SUSTAINED RELEASE INJECTABLES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN SUSTAINED RELEASE INJECTABLES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. GCC SUSTAINED RELEASE INJECTABLES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 161. GCC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. GCC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. GCC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 164. GCC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 165. GCC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 166. GCC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 167. GCC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 168. GCC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 169. GCC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION SUSTAINED RELEASE INJECTABLES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPEAN UNION SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS SUSTAINED RELEASE INJECTABLES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 187. BRICS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 188. BRICS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. G7 SUSTAINED RELEASE INJECTABLES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 191. G7 SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. G7 SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. G7 SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 194. G7 SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 195. G7 SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 196. G7 SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 197. G7 SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 198. G7 SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 199. G7 SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. NATO SUSTAINED RELEASE INJECTABLES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 201. NATO SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. NATO SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. NATO SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 204. NATO SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 205. NATO SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 206. NATO SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 207. NATO SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 208. NATO SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 209. NATO SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED STATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED STATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED STATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED STATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED STATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED STATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. CANADA SUSTAINED RELEASE INJECTABLES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 222. CANADA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. CANADA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. CANADA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 225. CANADA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 226. CANADA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 227. CANADA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 228. CANADA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 229. CANADA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 230. CANADA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. MEXICO SUSTAINED RELEASE INJECTABLES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 232. MEXICO SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. MEXICO SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. MEXICO SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 235. MEXICO SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 236. MEXICO SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 237. MEXICO SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 238. MEXICO SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 239. MEXICO SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 240. MEXICO SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 241. BRAZIL SUSTAINED RELEASE INJECTABLES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 242. BRAZIL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. BRAZIL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. BRAZIL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 245. BRAZIL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 246. BRAZIL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 247. BRAZIL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 248. BRAZIL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 249. BRAZIL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 250. BRAZIL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED KINGDOM SUSTAINED RELEASE INJECTABLES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED KINGDOM SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED KINGDOM SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED KINGDOM SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED KINGDOM SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED KINGDOM SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED KINGDOM SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED KINGDOM SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED KINGDOM SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED KINGDOM SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 261. GERMANY SUSTAINED RELEASE INJECTABLES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 262. GERMANY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. GERMANY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. GERMANY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 265. GERMANY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 266. GERMANY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 267. GERMANY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 268. GERMANY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 269. GERMANY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 270. GERMANY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 271. FRANCE SUSTAINED RELEASE INJECTABLES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 272. FRANCE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. FRANCE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. FRANCE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 275. FRANCE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 276. FRANCE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 277. FRANCE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 278. FRANCE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 279. FRANCE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 280. FRANCE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 281. RUSSIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 282. RUSSIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 283. RUSSIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. RUSSIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 285. RUSSIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 286. RUSSIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 287. RUSSIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 288. RUSSIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 289. RUSSIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 290. RUSSIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 291. ITALY SUSTAINED RELEASE INJECTABLES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 292. ITALY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 293. ITALY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 294. ITALY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 295. ITALY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 296. ITALY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 297. ITALY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 298. ITALY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 299. ITALY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 300. ITALY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 301. SPAIN SUSTAINED RELEASE INJECTABLES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 302. SPAIN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 303. SPAIN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 304. SPAIN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 305. SPAIN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 306. SPAIN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 307. SPAIN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 308. SPAIN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 309. SPAIN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 310. SPAIN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 311. CHINA SUSTAINED RELEASE INJECTABLES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 312. CHINA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 313. CHINA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 314. CHINA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 315. CHINA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 316. CHINA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 317. CHINA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 318. CHINA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 319. CHINA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 320. CHINA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 321. INDIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 322. INDIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 323. INDIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 324. INDIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 325. INDIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 326. INDIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 327. INDIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 328. INDIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 329. INDIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 330. INDIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 331. JAPAN SUSTAINED RELEASE INJECTABLES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 332. JAPAN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 333. JAPAN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 334. JAPAN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 335. JAPAN SUSTAINED RELEASE INJECTABLES MARKET